Chardan Capital Begins Coverage on Palvella Therapeutics (NASDAQ:PVLA)

Equities research analysts at Chardan Capital assumed coverage on shares of Palvella Therapeutics (NASDAQ:PVLA) in a report released on Wednesday, MarketBeat reports. The firm set a “buy” rating and a $50.00 price target on the stock. Chardan Capital’s price objective would indicate a potential upside of 151.64% from the stock’s previous close.

A number of other research analysts also recently commented on PVLA. TD Cowen assumed coverage on Palvella Therapeutics in a report on Wednesday, February 5th. They set a “buy” rating and a $44.00 target price on the stock. Scotiabank initiated coverage on Palvella Therapeutics in a research note on Friday, March 7th. They set a “sector outperform” rating and a $50.00 price objective on the stock. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $39.00 price objective on shares of Palvella Therapeutics in a report on Wednesday, February 26th. Cantor Fitzgerald began coverage on shares of Palvella Therapeutics in a report on Wednesday, December 18th. They set an “overweight” rating on the stock. Finally, Stifel Nicolaus started coverage on shares of Palvella Therapeutics in a report on Wednesday, March 26th. They issued a “buy” rating and a $45.00 price target for the company. Seven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Palvella Therapeutics presently has a consensus rating of “Buy” and an average price target of $44.43.

Palvella Therapeutics Price Performance

PVLA opened at $19.87 on Wednesday. The company has a market cap of $218.95 million, a P/E ratio of -1.64 and a beta of 0.10. The business has a 50-day moving average of $22.41. Palvella Therapeutics has a 1-year low of $6.20 and a 1-year high of $29.27.

Insider Transactions at Palvella Therapeutics

In other news, Director George M. Jenkins bought 2,500 shares of Palvella Therapeutics stock in a transaction on Wednesday, April 9th. The stock was purchased at an average cost of $20.13 per share, with a total value of $50,325.00. Following the purchase, the director now directly owns 183,171 shares of the company’s stock, valued at approximately $3,687,232.23. This trade represents a 1.38 % increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 6.39% of the company’s stock.

Institutional Investors Weigh In On Palvella Therapeutics

Hedge funds have recently made changes to their positions in the business. Toronto Dominion Bank bought a new position in Palvella Therapeutics in the 4th quarter worth approximately $159,000. Frazier Life Sciences Management L.P. bought a new position in shares of Palvella Therapeutics in the fourth quarter worth $7,847,000. Suvretta Capital Management LLC acquired a new position in shares of Palvella Therapeutics during the fourth quarter valued at $8,574,000. DAFNA Capital Management LLC acquired a new position in shares of Palvella Therapeutics during the fourth quarter valued at $857,000. Finally, Cresset Asset Management LLC bought a new stake in shares of Palvella Therapeutics during the fourth quarter valued at about $251,000. Institutional investors own 40.11% of the company’s stock.

About Palvella Therapeutics

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.